Connect with us

Special

6 things a gynaecologist wants you to know about endometriosis

By Dr Nitish Narvekar, fertility consultant at King’s Fertility and consultant gynaecologist at King’s College Hospital NHS Foundation Trust

Published

on

Despite the fact that endometriosis affects an estimated one in 10 women and girls globally, the condition is still widely misunderstood.

This Endometriosis Awareness Month, Dr Nitish Narvekar, clinical director and consultant gynaecologist at King’s College Hospital NHS Foundation Trust, discusses why endometriosis goes undiagnosed for years and shares what you should know about the condition.

What is endometriosis?

Endometriosis is a chronic debilitating inflammatory condition affecting up to 10 per cent of patients in their reproductive (puberty to menopause) years which equates to approximately over 1.5 million in the UK and 176 million globally.

The disease, where endometrial-like tissue grows outside the uterus, costs approximately £8bn per year to the UK economy in healthcare costs and loss of amenity.

Whilst the classic symptom is pelvic pain of varying intensity, duration and location, it can present with a range of other symptoms and conditions.

Signs and symptoms of endometriosis
  • Pain before and/or during periods (dysmenorrhea)
  • Pain during or after sex
  • Pain on opening bowels
  • Pain on passing urine
  • More frequent or urgent need to open bowels especially during periods
  • More frequent or urgent need to pass urine or waking up many times at night to pass urine
  • Blood in stools
  • Blood in urine
  • Cyclical chest pain and/or cough
  • Fatigue
  • Infertility > 6 months, especially if any of above is also present

Diagnosis is often delayed by eight to nine years due to lack of awareness by patients and care providers in all settings. Therefore, it is not uncommon for patients to be first diagnosed often fortuitously when undergoing a pelvic USS (ultrasound scan) or MRI (magnetic resonance imaging) when investigating other conditions, for example infertility.

USS is type of scan which uses high-frequency sound waves to create images of internal tissues/organs, whereas MRI uses strong magnetic fields and radio waves to produce such images.

Endometriosis and infertility

Whilst endometriosis is found in up to 50 per cent of patients with infertility, it is usually causative in patients with active disease and/or involvement of the fallopian tubes or ovaries. Whilst medical hormonal therapies are effective, they are not compatible with fertility and therefore many patients with complex endometriosis have to resort to surgery to improve fertility outcomes.

However, surgery carries attendant risks of trauma to bowel and urinary tract (also known as complications), and moreover, patients may experience delays in resuming fertility whilst recovering fully from surgery especially if it is complex.

Laparoscopy and endometriosis

Laparoscopy is a type of surgery which allows a surgeon to use keyhole cuts and a camera for procedures inside the tummy or pelvis.  It is the “gold standard” test for diagnosis and treatment of endometriosis and although invasive in nature is highly safe and effective.

Robotic surgery and endometriosis

Robotic surgery is a type of keyhole surgery undertaken using specialised camera and instruments which are inserted through keyhole cuts but unlike in laparoscopy these are controlled by a surgeon who sits at an ergonomically designed console away from the patient but otherwise in the same theatre.

Robotic surgery has been successfully introduced for routine gynaecological use in selected NHS clinics, for example King’s Fertility, and given its advantages, which include reduced complication rates and blood loss and faster recovery, has revolutionised surgical care of patients including when compared with traditional laparoscopy.

Whilst robotic surgery should be available to all patients, its use is limited by higher costs and limited availability and therefore at present reserved for managing patients with complex surgical and anaesthetic needs.

Another lesser known and heralded advantage of robotic surgery over and above other forms of surgery, including laparoscopy, is the greater ergonomics and intuitiveness it provides which in-turn results in reduced surgeon fatigue especially for complex cases. This in the long-run will improve working life and retention of surgeons at a time of greatest need within the NHS.

The pros of robotic surgery 

  • Greater precision
  • Superior 3D HD vision
  • Minimum tissue trauma
  • Nerve sparing
  • Lower blood loss and complications
  • Less post-operative pain
  • Reduced hospital stay
  • Quicker recovery
  • More ergonomic for the surgeon and reduced surgeon fatigue

The cons of robotic surgery

  • Higher capital costs
  • Rigorous quality and safety controls
  • Only available in select clinics and hospitals
What should women do?

All patients, including adolescents, should familiarise themselves with symptoms and signs of endometriosis and seek a GP appointment accordingly.

Where appropriate, patients should seek a high-quality pelvic USS, but, equally be aware that a negative USS does not rule out endometriosis and therefore, in case of persistent symptoms, seek additional MRI and/or laparoscopy and/or empirical treatments.

Patients with endometriosis should seek referral to a fertility clinic to discuss the nature of their condition and its impact on fertility. Many, but not all, fertility clinics provide high quality pelvic USS during initial diagnostic work-up and therefore benefit from quicker and more accurate diagnosis of endometriosis including deep and/or complex endometriosis.

Women with ovarian endometriosis and even otherwise, should consider preserving fertility by recourse to egg/embryo freezing where applicable.

Patients with severe and/or complex forms of endometriosis should request referral to their local BSGE (British Society of Gynaecological Endoscopy) accredited endometriosis centre.  Where possible they should enquire about availability of robotic surgery in such centres.

To receive the Femtech World newsletter, sign up here.

News

Jill Biden visits Imperial on women’s health and AMR mission

Published

on

Former US first lady Dr Jill Biden visited Imperial College Healthcare NHS Trust and Imperial College London to explore work on women’s health and antimicrobial resistance.

The visit was hosted by professor the Lord Darzi of Denham, who chairs the Fleming Initiative and directs Imperial’s Institute of Global Health Innovation.

Dr Biden, chair of the Milken Institute’s Women’s Health Network, spoke about the impact scientists, clinicians, innovators and investors can have on improving women’s healthcare.

Dr Biden stressed the importance of “collaboration, prevention and education” in improving women’s health globally.

At the museum, Dr Biden and Esther Krofah, executive vice-president of health at the Milken Institute, heard about the worldwide significance of the discovery and the contribution of women who, during wartime Britain, grew penicillin in bedpans to support early experimentation.

The discussion also explored how AMR is a key women’s health issue, with women disproportionately affected in low and middle-income countries, and in high-income settings where women are more likely than men to be prescribed antibiotics.

Dr Biden was shown an architectural model of the Fleming Centre in Paddington, which will bring together research, policy and public engagement to address AMR worldwide.

The second part of the visit brought together Imperial clinicians, researchers and innovators for a roundtable on women’s health priorities, including improving diagnosis, equity in maternity care and support during the menopause transition.

Participants highlighted wide variation in the quality of care for conditions affecting women and called for fairer access to services, with the postcode lottery named as a priority to address.

Professor Tom Bourne, consultant gynaecologist and chair in gynaecology at Imperial’s Department of Metabolism, Digestion and Reproduction, described how AI could improve diagnostic accuracy for conditions such as endometriosis.

Equity emerged as a central theme.

Professor Alison Holmes, professor of infectious diseases at Imperial College London and director of the Fleming Initiative, highlighted persistent gaps in women’s representation in clinical trials, including antibiotic studies, which limits the ability to optimise care and treatments.

Dr Christine Ekechi, consultant obstetrician and gynaecologist at Imperial College Healthcare NHS Trust, drew on national maternity investigations to underline the importance of valid data, meaningful engagement with affected communities and rebuilding trust.

Menopause and midlife health were also identified as priorities for clinical research.

Professor Waljit Dhillo, consultant endocrinologist and professor of endocrinology and metabolism in Imperial’s Department of Metabolism, Digestion and Reproduction, described a new treatment for hot flushes, including for women unable to take hormone replacement therapy, such as those with a history of breast cancer.

The discussion then turned to bringing innovation into health systems. Innovators shared how data and technology are being used to close gaps in women’s health, while noting challenges in accessing funding to grow and scale.

Dr Helen O’Neill and Dr Deidre O’Neill, co-founders of Hertility Health, described predictive algorithms using self-reported data to help diagnose gynaecological conditions at scale.

Embedded into clinical workflows, the technology could reduce waiting times, identify conditions earlier and improve outcomes. They noted how “we have cures for the rarest genetic conditions but don’t even have the answers to common women’s health issues.”

Dr Lydia Mapstone, Dr Tara O’Driscoll and Dr Sioned Jones, co-founders of BoobyBiome, outlined work creating products that harness beneficial bacteria found in breast milk to support infant health.

By isolating and characterising key microbial strains, BoobyBiome has created synbiotics, combinations of beneficial bacteria and the food that nourishes them, to make these benefits accessible to all babies.

Speakers throughout the visit stressed the need to reduce variation in care quality and outcomes for women, strengthen prevention and education, and address power and equity in women’s health.

Professor the Lord Ara Darzi said: “It was a privilege to welcome Dr Biden and the Milken Institute to Imperial to meet some of the outstanding researchers, clinicians and innovators advancing women’s health.

“Imperial’s unique combination of clinical excellence and world-leading research positions us at the forefront of tackling the biggest health challenges facing society and the UK’s ambition for innovation demands nothing less.

“For too long, the health needs of women and girls across their life course have not received the attention they deserve.

“By working together across borders and disciplines, we can transform equitable access to care, accelerate the detection and treatment of disease, and ultimately improve health outcomes for millions of women in the UK and around the world.”

Continue Reading

Special

AHA campaign to raise awareness of heart disease in women

Published

on

Fashion, beauty and lifestyle retailers have joined the American Heart Association to raise awareness of heart disease in women.

The Go Red. Shop with Heart. campaign launched at the New York Stock Exchange on 30 January.

Retailers will ask for donations at checkout in February or donate a percentage of proceeds from selected items.

More than four in 10 women in the US have some form of cardiovascular disease, a term for heart and blood vessel conditions such as heart disease and stroke.

Heart disease and stroke kill more women in the US each year than all forms of cancer combined.

Brands taking part include Away, Commando, Lafayette 148, Michael Kors, Reebok, ShopSimon.com, Summersalt, Torrid and White & Warren.

More than 40 other nationwide retailers are also inviting customers to support the organisation this February through its Life Is Why campaign.

Nancy Brown is chief executive officer of the American Heart Association.

She said: “Nearly 1 in 3 women die from cardiovascular disease each year, yet women are still profoundly under-represented in the clinical research, science and medicine that could save their lives.

“Retailers and consumers are uniquely positioned to turn everyday moments into meaningful change through Go Red. Shop with Heart.”

According to the American Heart Association 2026 Heart Disease and Stroke Statistics Update, heart disease is the leading cause of death in the US and stroke is the number four cause of death.

The organisation projects that at least six in 10 US adults will have cardiovascular disease within the next 30 years and related costs are expected to triple.

However, approximately 80 per cent of cardiovascular disease is preventable through lifestyle changes.

Mindy Grossman is a volunteer board member at the American Heart Association and partner and vice chair of Consello.

Grossman said: “Retail has always been a powerful connector.

“Shop with Heart gives our industry a shared platform to lead with purpose and unite consumers in support of heart health.”

Continue Reading

Insight

Milken launches women’s health network platform

Published

on

Milken Institute has launched the Women’s Health Network digital platform with Velir x Brooklyn Data to speed collaboration and investment across research, care and technology.

The new website creates a hub for members to share content, connect and coordinate projects, with branding and the first public Drupal build delivered by Velir x Brooklyn Data. A launch video premiered on 4 November 2025 at the inaugural steering committee and member luncheon in Washington DC, then featured at the Milken Institute Future of Health Summit.

Phase two is scheduled for February 2026, adding member log-ins for networking and content exchange. Phase three in April 2026 will add advanced collaboration tools and expanded community features.

“This launch represents the type of mission-driven, cross-sector digital work we are incredibly proud to support,” said Eliza Pare, vice-president of client services at Velir. “The Women’s Health Network is poised to transform collaboration in women’s health, and we’re honoured to help build the digital infrastructure that will make that possible.”

Chaired by former first lady Dr Jill Biden, the Women’s Health Network brings together leaders from industry, startups, investors, health systems, patient groups, academia and philanthropy. More than 100 members have joined, with a steering group that includes organisations such as the American Cancer Society, American Heart Association, Amgen, Deloitte, GE Healthcare, Merck, Microsoft, Northwell Health, Organon and others.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.